Carl Robinson
Neurology · Lewiston, MENPI 1639103997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 30.3% of the total. Reporting peaked in 2019 at $906 and has fallen 72.2% since, to $252 in 2023.
Across 169 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$940
- Novartis$251
- Biogen$230
- EMD Serono, Inc.$181
- Sunovion Pharmaceuticals Inc.$170
- Lilly USA, LLC$147
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$662%
- Food & beverage$3,04398%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $940 |
| Novartis | 15 | $251 |
| Biogen | 13 | $230 |
| EMD Serono, Inc. | 11 | $181 |
| Sunovion Pharmaceuticals Inc. | 10 | $170 |
| Lilly USA, LLC | 8 | $147 |
| Sanofi | 7 | $128 |
| Amgen(2 entities) | 6 | $114 |
| AstraZeneca | 6 | $109 |
| Teva Pharmaceuticals USA, Inc. | 7 | $108 |
| Neurocrine Biosciences, Inc. | 5 | $85 |
| SK Life Science, Inc. | 4 | $77 |
| Genentech USA, Inc. | 5 | $77 |
| Acorda Therapeutics, Inc | 4 | $66 |
| GE HealthCare | 3 | $61 |
| Mallinckrodt Enterprises LLC | 2 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Grifols USA, LLC | 2 | $44 |
| Greenwich Biosciences, Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| TG Therapeutics, Inc. | 1 | $24 |
| Livanova USA, Inc. | 1 | $23 |
| Pfizer | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| CSL Behring | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$125
How this compares
$3,109 in reported general payments places this provider in the 75th percentile of 69 neurology providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 25 | $18,076 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,271 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $173 |
| Donepezil Hcl | 12 | $88 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lewiston
- David BurkeLewiston$4K
- Anthony KnoxYork$380K
- John DolanPortland$370K
- Heidi HenningerScarborough$350K
- Aashoo MentreddiYork$176K
- Alexander AbudRockport$113K
- Alexandra DegenhardtRockport$65K
- Alison DaigleSouth Portland$50K
- Helia MaghziScarborough$37K
- Edward DrasbyScarborough$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.